|
|
| Line 1: |
Line 1: |
| {{drugbox |
| | #REDIRECT [[Thioguanine]] |
| | IUPAC_name = 2-amino-7H-purine-6-thiol
| |
| | image = Tioguanine.png
| |
| | CAS_number = 154-42-7
| |
| | ATC_prefix = L01
| |
| | ATC_suffix = BB03
| |
| | PubChem = 2723601
| |
| | DrugBank = APRD00290
| |
| | C=5 | H=5 | N=5 | S=1
| |
| | molecular_weight = 167.193 g/mol
| |
| | bioavailability = 30% (range 14% to 46%)
| |
| | protein_bound =
| |
| | metabolism = Intracellular
| |
| | elimination_half-life = 80 minutes (range 25-240 minutes)
| |
| | excretion =
| |
| | pregnancy_category =
| |
| | legal_status =
| |
| | routes_of_administration = oral
| |
| }}
| |
| {{SI}}
| |
| | |
| | |
| ==Overview==
| |
| '''Tioguanine''' ([[International Nonproprietary Name|INN]]), formerly '''Thioguanine''' ([[British Approved Name|BAN]]), is a [[medication|drug]] that is used in the treatment of [[cancer]]. It belongs to the family of drugs called [[antimetabolite]]s. It is a [[guanine]] analog. Its principal use is in [[acute leukaemia]]s and [[chronic myeloid leukaemia]].
| |
| | |
| ==Pharmacology==
| |
| As a guanine analogue, it is transformed inside the cell into to 6-thioguanilyic acid (TGMP) which, by pseudofeedback interference with purine biosynthesis, interferes with the synthesis of guanine nucleotides. Some of its activity may also be due to the incorporation of thioguanine nucleotides into both [[RNA]] and [[DNA]], but the end result is inducing [[cell cycle]] arrest and [[apoptosis]]. It is metabolized by via methylation by [[thiopurine methyltransferase]].
| |
| | |
| {{Chemotherapeutic agents}}
| |
| | |
| [[Category:Chemotherapeutic agents]]
| |
| | |
| | |
| [[de:Tioguanin]]
| |
| [[ru:Тиогуанин]]
| |
| {{WH}}
| |
| {{WikiDoc Sources}}
| |